Why This Matters
Tens of millions of Americans are now taking or are about to start a GLP-1 receptor agonist for weight loss, obesity management, or type 2 diabetes. Most are focused on what the drugs do for their weight, blood sugar, and cardiovascular risk. Few are asking what these drugs may be doing to their bones.
A study published in the Journal of Clinical Endocrinology and Metabolism in July 2026 provides reason to ask that question specifically. Researchers found that patients using semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) experienced significantly greater annualized total hip bone loss than matched controls, particularly among patients who were taking these drugs for weight loss without type 2 diabetes as an underlying condition.
The finding is not a reason to stop GLP-1 medications or to avoid them. It is a reason to build a bone health plan before and during treatment, particularly for the patients who already face elevated fracture risk: postmenopausal women, adults over 65, and anyone with pre-existing osteopenia or osteoporosis.
What We Know So Far
The July 2026 study, published in the Journal of Clinical Endocrinology and Metabolism (Volume 111, Issue 7, Pages 1959-1966, DOI: 10.1210/clinem/dgag052), was a single-center retrospective study from researchers including Yi Liu, Dalia Walzer, and Emily M. Stein. The study enrolled 255 patients using semaglutide or tirzepatide for at least 6 months who had undergone DXA scans (bone density measurements) before and after starting the drugs. They were matched to 255 control patients of similar age, sex, BMI, and diabetes status who had not used GLP-1 medications.
After a median follow-up of 17 months, the GLP-1 group achieved a median 5% weight loss. The primary bone finding was an increase in the annualized rate of total hip bone loss among GLP-1 users without diabetes compared to matched controls. The difference was statistically significant. Among patients with type 2 diabetes, the bone loss was comparable between GLP-1 users and controls, suggesting that the mechanism may relate more closely to weight loss itself than to any direct effect of the drug on bone biology.
A separate 52-week randomized controlled trial from Hansen et al. (2024, eClinicalMedicine) had previously found that semaglutide reduced bone mineral density at the lumbar spine and total hip compared to placebo in 64 adults at increased fracture risk, predominantly postmenopausal women. That trial found bone resorption markers increased while bone formation markers did not compensate, a pattern called uncoupling that is associated with net bone loss over time.
Where the Risk Is Highest
The subgroup analysis in the JCEM study is clinically significant: the bone loss signal was concentrated in GLP-1 users without diabetes, where weight loss is the primary mechanism of action. The researchers' conclusion is that rapid weight loss, rather than any direct pharmacological effect of the drugs on bone cells, may be the primary driver of bone density reduction. Bones respond to mechanical loading: when body weight drops substantially, the physical stress placed on bone structure decreases, and bone-remodeling biology shifts toward net resorption.
At baseline in the JCEM study, 56% of patients in the GLP-1 group had osteopenia (below-normal bone density) and 14% had osteoporosis. By follow-up, those proportions rose to 60% and 16%, respectively. These were patients who were already at elevated fracture risk before starting GLP-1 therapy, according to Endocrinology Advisor's reporting on the study.
The populations most directly in the line of this risk are:
- Postmenopausal women using GLP-1 drugs for weight loss without diabetes, who already have accelerated bone resorption from estrogen decline
- Adults over 65 who are initiating GLP-1 therapy, given age-related bone density decline
- People who started GLP-1 drugs with low body weight or pre-existing osteopenia
-
People who are losing weight rapidly, as the magnitude of weight loss appears to correlate with the degree of bone loss
What Doctors and Experts Say
Dr. Jeremy Burnham, a sports medicine physician at Ochsner-Andrews who has written on GLP-1 and musculoskeletal health, has noted that prescribing GLP-1 medications without a musculoskeletal protection plan is "incomplete care" for patients with multiple overlapping risk factors. The cumulative risk, he argues, is what matters. Postmenopausal women face compounding biological pressures: estrogen decline already accelerates bone resorption, and the Hansen trial specifically enrolled adults with increased fracture risk.
The study authors concluded in their abstract that GLP-1 receptor agonists' effects on bone "may differ by DM status, with weight loss driving bone loss in patients without DM." That interpretation, if correct, suggests the solution is not avoiding GLP-1 therapy but pairing it with evidence-based bone protection, including resistance exercise to maintain mechanical loading on bone, adequate calcium and vitamin D intake, and baseline and follow-up DXA screening for high-risk patients.
Dr. Stein and colleagues noted that larger, prospective longitudinal studies are needed to confirm these findings and to determine whether the bone changes translate into increased fracture rates in clinical practice. The fracture outcome question is ultimately the most important one and remains unanswered.
What the Evidence Shows and What It Does Not
The JCEM study is a single-center retrospective study with 255 GLP-1 users. It measured DXA-based bone mineral density, not fracture rates. The finding of greater annualized hip bone loss is meaningful but does not establish that GLP-1 users face a higher fracture rate in clinical practice. Bone density changes and fracture risk are correlated but not identical.
The study cannot establish causation. Patients who chose GLP-1 therapy may differ from matched controls in ways that affect bone density independently of the medication, though propensity matching was used to control for known confounders.
MedicalDaily Evidence Check
- Study type: Single-center retrospective matched cohort study
- Published in: Journal of Clinical Endocrinology and Metabolism, Volume 111, Issue 7, July 2026 (DOI: 10.1210/clinem/dgag052)
- Participants: 255 GLP-1 users (semaglutide or tirzepatide) matched to 255 controls; median follow-up 17 months
- What it found: Significantly greater annualized total hip bone loss in GLP-1 users without diabetes vs. matched controls; no significant difference in GLP-1 users with diabetes vs. controls
- What it did not prove: That GLP-1 drugs cause fractures; causal mechanism not established; fracture outcome data not available from this study
-
What readers should know: This is a legitimate safety signal requiring prospective investigation; the finding does not mean patients should stop GLP-1 therapy but does mean bone health assessment should be part of the treatment conversation
Who Faces the Greatest Risk?
Patients who should proactively discuss this finding with their prescribing physician include:
- Postmenopausal women initiating or currently using GLP-1 drugs for weight loss without diabetes
- Adults 65 and older taking any GLP-1 medication
- Patients with a prior fragility fracture or documented osteoporosis
- Patients with low body weight or low BMI who begin GLP-1 therapy (they have less weight-based mechanical loading to begin with)
-
People with conditions that independently affect bone density, including celiac disease, inflammatory bowel disease, prolonged corticosteroid use, or thyroid disease
Symptoms and Warning Signs to Watch For
Bone density loss is typically silent until a fracture occurs. People on GLP-1 therapy should watch for:
- Back pain that may indicate a vertebral compression fracture
- Any fall, even from standing height, that results in a fracture (a fragility fracture)
- Gradual height loss over years, which can indicate vertebral fractures
- Hip, wrist, or shoulder pain after minor trauma
These are not early warning signs of bone thinning in real time. They are reasons to report to a physician promptly and discuss whether bone density evaluation is indicated.
What You Can Do Now
- If you are currently on a GLP-1 medication and have not had a bone density DXA scan in the past two years, ask your clinician whether one is appropriate given your age, menopause status, and fracture history.
- Resistance exercise, meaning weight-bearing and strengthening exercise with adequate load, is the most effective behavioral intervention for maintaining bone density during weight loss. Walking alone is not sufficient; exercises that load the hips and spine (squats, deadlifts, step-ups, resistance bands) produce the mechanical stimulus that prevents bone resorption.
- Ensure adequate calcium and vitamin D intake. Adults over 50 need approximately 1,200 mg of calcium daily and 800 to 1,000 IU of vitamin D daily. Ask your physician whether supplementation is appropriate for your situation.
- Discuss with your prescribing physician whether a follow-up DXA scan should be planned at 12 to 24 months after starting GLP-1 therapy.
-
Do not stop a GLP-1 medication without speaking with your physician. The cardiovascular, metabolic, and weight-loss benefits of these drugs are substantial. The goal is to protect bone health simultaneously, not to forgo the benefits of treatment.
Cost and Access: What Patients Should Know
DXA bone density scans are covered by Medicare for women over 65 and for men and women with established osteoporosis risk factors. For younger patients, coverage depends on the insurance plan and clinical indication. Many imaging centers offer cash-pay DXA scans for $50 to $150.
Calcium and vitamin D supplements are inexpensive and available over the counter. Prescription osteoporosis medications, if indicated, are covered by most insurance plans and Medicare Part D with appropriate clinical documentation.
What Happens Next
Larger prospective studies with fracture outcomes are needed and are expected to be initiated given the clinical significance of this signal. The FDA has not issued any specific guidance on bone density monitoring for GLP-1 therapy, but clinical societies in endocrinology and orthopedics are expected to address this in upcoming practice guidelines.
MedicalDaily will continue reporting on bone health and GLP-1 therapy as prospective data and clinical guidance emerge.
The Bottom Line
A July 2026 study found that patients taking semaglutide or tirzepatide for weight loss without diabetes experienced significantly more hip bone loss over 17 months than matched controls. The signal is real and clinically relevant, particularly for postmenopausal women and older adults who are already at elevated fracture risk. The appropriate response is not to avoid GLP-1 therapy, which offers substantial benefits, but to discuss baseline bone density, plan follow-up DXA imaging, maintain resistance exercise, and ensure adequate calcium and vitamin D throughout treatment. This is a conversation that should be happening in every GLP-1 prescribing encounter for high-risk patients.
